Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rezolute Inc (RZLT)

Rezolute Inc (RZLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,311
  • Shares Outstanding, K 92,728
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,410 K
  • EBIT $ -83 M
  • EBITDA $ -85 M
  • 60-Month Beta 0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.11

Options Overview Details

View History
  • Implied Volatility 132.22% (-18.06%)
  • Historical Volatility 602.39%
  • IV Percentile 26%
  • IV Rank 5.52%
  • IV High 1,264.34% on 04/04/25
  • IV Low 66.01% on 07/07/25
  • Expected Move (DTE 2) 0.2550 (12.62%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 5,254
  • Volume Avg (30-Day) 6,917
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 92,106
  • Open Int (30-Day) 55,785
  • Expected Range 1.7650 to 2.2750

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +88.79%
on 12/11/25
11.1600 -81.91%
on 12/10/25
-7.8500 (-79.53%)
since 11/14/25
3-Month
1.0700 +88.79%
on 12/11/25
11.4600 -82.37%
on 11/10/25
-5.7000 (-73.83%)
since 09/16/25
52-Week
1.0700 +88.79%
on 12/11/25
11.4600 -82.37%
on 11/10/25
-2.4700 (-55.01%)
since 12/16/24

Most Recent Stories

More News
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm

SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after...

RZLT : 2.0200 (+23.93%)
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

RZLT Investors with Losses Encouraged to Contact the Firm

RZLT : 2.0200 (+23.93%)
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its...

RZLT : 2.0200 (+23.93%)
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

The DJS Law Group announces that it is investigating claims on behalf of investors of Rezolute, Inc. (“Rezolute” or “the Company”) (NASDAQ: RZLT ) for violations of the securities...

RZLT : 2.0200 (+23.93%)
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss...

RZLT : 2.0200 (+23.93%)
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management...

RZLT : 2.0200 (+23.93%)
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused...

RZLT : 2.0200 (+23.93%)
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused...

RZLT : 2.0200 (+23.93%)
Rezolute to Host Virtual Investor Event on Ersodetug Development Program

REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused...

RZLT : 2.0200 (+23.93%)
Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused...

RZLT : 2.0200 (+23.93%)

Business Summary

Rezolute, Inc. is a biopharmaceutical company specializing in the development of drug therapies for metabolic and orphan diseases. The Company's products include AB101, RZ358, RZ402 and RZ602 which are in clinical stage. Rezolute, Inc., formerly known as AntriaBio, Inc., is based in LOUISVILLE, United...

See More

Key Turning Points

3rd Resistance Point 2.7200
2nd Resistance Point 2.4200
1st Resistance Point 2.2200
Last Price 2.0200
1st Support Level 1.7200
2nd Support Level 1.4200
3rd Support Level 1.2200

See More

52-Week High 11.4600
Fibonacci 61.8% 7.4900
Fibonacci 50% 6.2600
Fibonacci 38.2% 5.0400
Last Price 2.0200
52-Week Low 1.0700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar